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S U M M A R Y
Objective: This study aimed to assess the performance of a laboratory-developed recombinant CFP-10/
ESAT-6 fusion protein (rCFP-10/ESAT-6)-based enzyme-linked immunospot (ELISPOT) assay for the
diagnosis of spinal tuberculosis (TB) in China, and to evaluate the value of the ELISPOT assay for
monitoring the efﬁcacy of surgical treatment.
Methods: In the ﬁrst part of the study, a total of 78 participants were consecutively recruited for ELISPOT
using rCFP-10/ESAT-6 as a stimulus. The cutoff value for ELISPOT positivity was based on the results of
receiver operating characteristic curve analysis. In the second part, this approach was evaluated in a
prospective study including 102 patients with suspected spinal TB. Data on clinical characteristics of the
patients and conventional laboratory results were collected, and blood samples were obtained for
ELISPOT using rCFP-10/ESAT-6 as a stimulus.
Results: Among the 102 patients with suspected spinal TB, 11 were excluded from the study. Twenty-
three patients (25.2%) had culture-conﬁrmed TB and 29 (31.9%) patients had probable TB. Among the
spinal TB patients, the ELISPOT had a sensitivity of 82.7%, compared to a sensitivity of 61.5% for the
puriﬁed protein derivative (PPD) skin test. The speciﬁcity was 87.2% for ELISPOT and 46.2% for the PPD
skin test among 39 subjects with non-TB disease. The number of spot-forming cells and/or the positive
rate of the ELISPOT assay were associated with aging, emaciation, and paravertebral abscess. The number
of subjects with responses to rCFP-10/ESAT-6 slightly decreased after surgical treatment in spinal TB
patients.
Conclusions: A laboratory-developed rCFP-10/ESAT-6 ELISPOT assay is a useful adjunct to current tests
for the diagnosis of spinal TB.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Spinal tuberculosis (TB) is found in 1–3% of all TB cases and in
50–60% of cases of musculoskeletal TB.1 However, the diagnosis of
spinal TB is difﬁcult to set, not only because of its nonspeciﬁc
clinical presentation, but also because of the lack of useful
diagnostic tests. Diagnostic methods used for spinal TB are
tuberculin skin testing, radiographic image examination, culture,
and PCR assays. Tuberculin skin testing is a conventional test with
a sensitivity ranging from 67% to 72%, but it cannot differentiate
between active and past infections and can also be positive due to
bacille Calmette–Gue´rin (BCG) vaccination.2 Most importantly,* Corresponding author. Tel.: +86 20 61641723; fax: +86 20 87640940.
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1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.02.027conﬁrmation testing by mycobacterial culture is time-consuming
and often takes weeks to complete. Thus, there is a need for a rapid
and accurate diagnostic test.
An in vitro T-SPOT-TB assay using pools of early secretory
antigenic target 6 (ESAT-6) and culture ﬁltrate protein 10 (CFP-10)
peptides, has recently been manufactured and commercialized
(Oxford Immunotec, Oxford, UK).3 It is based on the detection of
interferon-gamma (IFN-g) released by activated T lymphocytes.
The stimuli used, ESAT-6 and CFP-10 peptides, are located within
region of difference 1 (RD1) of the Mycobacterium tuberculosis and
Mycobacterium bovis genomes, but is absent from all strains of M.
bovis BCG, as well as from most non-tuberculous mycobacteria
(NTM).4–6 This assay has been demonstrated to provide useful
support in the diagnosis of skeletal TB.7,8 However, the use of
peptides increases the cost of the kit, making it unaffordable in
developing countries. A fusion protein as the stimulus would offerses. Published by Elsevier Ltd. All rights reserved.
Table 1
Epidemiological and demographic characteristics of 91 patients with suspected
spinal TB
Variables Deﬁnite TB
(n = 52)
Non-TB disease
(n = 39)a
Age, years, mean  SD (range) 42.3  18.4
(2–86)
46.5  13.9
(18–69)
Male to female sex ratio 31:21 17:22
Underlying condition or illness (%)
Hypertension 3 (6) 7 (18)
Pneumonia 1 (2) 2 (5)
Hepatitis B 5 (10) 0
Syphilis 2 (4) 1 (3)
Diabetes mellitus 3 (6) 2 (5)
Immunocompromised conditionb (%) 10 (19) 2 (5)
Suspected sites of infection (%)
Cervical vertebra 0 6 (15)
Thoracic vertebra 22 (42) 5 (13)
Thoraco-lumbar 5 (10) 0
Lumbar vertebra 23 (44) 28 (72)
Sacral vertebrae 2 (4) 0
Combined pulmonary TB (%) 7 (13) 2 (5)
TB, tuberculosis; SD, standard deviation. Data are presented as number (%).
a Non-TB disease: sixteen patients with lumbar disc herniation; six patients with
cervical spondylosis; eight patients with spinal canal tumor; ﬁve patients with
spinal tumor; four patients with suppurative spondylitis.
b Immunocompromised patients were deﬁned as those with underlying diseases
such as malignancy, liver cirrhosis, and chronic renal failure, or those receiving
immunosuppressive treatment.12
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and clinical use in developing countries. A laboratory-
developed recombinant CFP-10/ESAT-6 fusion protein (rCFP-
10/ESAT-6)-based enzyme-linked immunospot (ELISPOT) as-
say has been demonstrated to be useful for the diagnosis of
active pulmonary TB in China.9 The aim of this study was to
assess the diagnostic value of a laboratory-developed rCFP-10/
ESAT-6 ELISPOT assay in clinical cases of spinal TB in China. In
subgroups of subjects, we repeated the assay before and after
surgical treatment to assess the evolution of responses. To our
knowledge, this is the ﬁrst clinical evaluation of rCFP-10/
ESAT-6 as the stimulus in an ELISPOT assay for the diagnosis
of spinal TB and for monitoring the efﬁcacy of surgical
treatment.
2. Materials and methods
2.1. Participants and study design
Participants were consecutively recruited at two hospi-
tals (Nanfang Hospital, Southern Medical University, an
1800-bed medical center in southern China; Guangzhou
Thoracic Hospital, a 600-bed medical center in southern
China) from May 2011 to September 2012. Ethical approval
for the study was granted by the ethics committee of
Nanfang Hospital.
In phase 1, 78 participants were consecutively enrolled into the
study. Patients were untreated or had received <2 weeks of anti-
TB therapy at the time of venipuncture for the ELISPOT assay. Fifty
cases had a ﬁnal diagnosis determined according to the following
criteria: patients classiﬁed as having conﬁrmed TB were those
with clinical specimens positive for M. tuberculosis on culture;
patients were classiﬁed as having probable TB if histological
ﬁndings of a biopsy specimen were consistent with a diagnosis of
TB infection (granulomatous inﬂammation and/or caseating
necrosis) and if they responded clinically and radiologically to
a full course of anti-TB treatment according to the criteria
described in previous studies;10,11 patients were classiﬁed as not
having TB if another diagnosis was made or if there was clinical
improvement without anti-TB therapy. Enrolled participants
included 30 spinal TB patients, 20 non-TB patients, and 28
healthy volunteers. Based on the rCFP-10/ESAT-6 ELISPOT results
of these participants, receiver operating characteristic curve
analysis was performed to determine the optimal cutoff value of
the ELISPOT assay.
In phase 2, a total of 102 patients with suspected spinal TB were
prospectively recruited during the study period. Data on clinical
characteristics of the patients and conventional laboratory results
were collected. The speciﬁc data collected were age, sex,
underlying diseases, radiographic image examination, lympho-
cyte count, pathology, microbiology results, and follow-up
observations. All cases were independently classiﬁed by two of
the study investigators (QZ, JC) who were blinded to the ELISPOT
assay results. Diagnostic criteria were based on the above
standard. After a follow-up to September 2012, 11 patients were
excluded from the study, among whom ﬁve did not complete the
ELISPOT assay and six had no ﬁnal diagnosis. The remaining 91
patients were ultimately included for ELISPOT analyses. The
spinal TB group consisted of 52 cases (23 conﬁrmed cases and 29
probable cases), with a mean age of 42.3  18.4 years (range 2–86
years). The non-TB disease group consisted of 39 subjects, with a
mean age of 46.5  13.9 years (range 18–69 years). All patients
enrolled in the present study were tested for HIV by serology and all
had negative results. Details of the 91 patients with suspected spinal
TB are shown in Table 1.122.2. Laboratory procedures and histopathology
Microbiological and pathological specimens for diagnosing
spinal TB were processed by standard techniques and procedures.
In brief, mycobacteria were cultured on solid culture medium, and
the M. tuberculosis complex was identiﬁed with a commercial DNA
probe (AccuProbe Mycobacterium TB complex culture identiﬁca-
tion kit; GenProbe, San Diego, CA, USA). If the AccuProbe assay was
negative, cultures were identiﬁed with a commercially available
PCR test for NTM (kit for the identiﬁcation and drug sensitivity
testing of non-tuberculous Mycobacterium; Gaoteng, Nanchang,
China). For histopathological examination, formalin-ﬁxed and
parafﬁn-embedded tissue blocks of biopsied specimens were
stained with hematoxylin–eosin stain. Smears of the decontami-
nated specimens were stained with the Ziehl–Neelsen stain and
examined for acid-fast bacilli (AFB).
2.3. Preparation of rCFP-10/ESAT-6 fusion protein
The fusion protein of CFP-10 (Rv3874) and ESAT-6 (Rv3875)
was engineered as described previously.13–15 In brief, the
individual genes were ampliﬁed from M. tuberculosis H37Rv
genomic DNA by PCR. During the ampliﬁcation steps the genes
were fused with a linker encoding glycine–glycine–glycine–
glycine–serine–glycine–glycine–glycine–glycine–serine–glycine–
glycine–glycine–glycine–serine. The product was subsequently
cloned into plasmid vector pET-28a (Novagen, San Diego, CA, USA)
containing a C-terminal hexa-histidine tag. Sequencing was
performed to conﬁrm the identity of the cloned DNA fragment.
The recombinant fusion protein was over-expressed in Escherichia
coli BL21 (DE3) (Invitrogen, Carlsbad, CA, USA) and was puriﬁed by
metal chelate column chromatography using nickel–nitrilotriace-
tic acid (Ni–NTA) resin in accordance with the manufacturer’s
protocol (Qiagen). Recombinant protein batches were analyzed by
15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), followed by Coomassie brilliant blue staining and
Western blotting with a murine anti-His tag monoclonal antibody
(Novagen, San Diego, CA, USA), to conﬁrm the size and purity of the
protein.
Figure 1. Representative results of the laboratory-developed rCFP-10/ESAT-6
ELISPOT assay from three patients. (A) Negative result from a non-spinal TB disease
patient. (B) Negative result from a spinal TB patient. (C) Positive result from a spinal
TB patient. Lane 1: negative control, in which 2.5  105 PBMCs were unstimulated;
lane 2: positive control, in which 2.5  105 PBMCs were stimulated by PHA; lane 3:
test well, in which PBMCs were stimulated by rCFP-10/ESAT-6 antigen.
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A laboratory-developed rCFP-10/ESAT-6 ELISPOT assay for
IFN-g was performed as described previously.9 Four to ﬁve
milliliters of venous blood samples from the volunteers were
taken in heparinized glass tubes, and peripheral blood mononu-
clear cells (PBMC) were isolated and quantiﬁed the second day
after the patients went into hospital. PBMC, 250 000 cells/well,
were seeded in 96-well plates (Millipore, USA) pre-coated with
anti-IFN-g capture monoclonal antibody (Mabtech AB, Sweden)
and stimulated with the different antigens for 20 h at 37 8C in air
plus 5% CO2. rCFP-10/ESAT-6 fusion protein, 40 mg/ml, was used
as the speciﬁc antigenic stimulus. PBMC in medium alone and
phytohemagglutinin (PHA, Sigma, USA) at 10 mg/ml were used as
negative and positive controls, respectively. Biotinylated anti-
IFN-g detection monoclonal antibody (Mabtech AB, Sweden) was
added for 1 h at 37 8C, followed by the addition of streptavidin–
alkaline phosphatase conjugate (Mabtech AB, Sweden) for 30 min
at room temperature. After a washing step, the nitroblue
tetrazolium (NBT) and 5-bromo-4-chloro-3-indolylphosphate
(BCIP; Mabtech AB, Sweden) chromogenic substrate were added.
The number of spot-forming cells (SFC) in each well was
automatically counted with a CTL-ImmunoSpot S5 Versa Analyzer
(Cellular Technology Ltd, USA). The responses were scored as
positive if the test well contained at least 15 more SFC than the
negative control well or had at least twice as many SFC as the
negative control well. PHA-positive control wells were set to at
least 100 SFC/well/250 000 cells. Negative control wells were
required to have <15 SFC.
2.5. Puriﬁed protein derivative (PPD) skin test and serological
(antibody detection) test
PPD produced from M. tuberculosis (50 IU/ml) was purchased
from Guangzhou Longcheng Technology Inc., China. All patients
with suspected spinal TB were injected intradermally in the left
forearm with 0.1 ml of 5 IU PPD (Mantoux technique) after
extraction of blood for the ELISPOT. The diameters of both axes of
the skin induration were measured and recorded by two certiﬁed
doctors (QZ, JC) at 72 h after antigen injection. Results were
expressed as the mean of the diameter of induration in millimeters.
A positive result was deﬁned as an induration 5 mm in diameter.
For the serological (antibody detection) test, spinal TB was
identiﬁed with a commercial antibody (IgG) detection kit
(diagnostic kit for IgG antibody to M. tuberculosis; Yaji Inc.,
Shanghai, China).
2.6. Data management and statistical analysis
All data were entered into a Microsoft Ofﬁce Excel ﬁle.
Diagnostic performance was expressed in terms of sensitivity,
speciﬁcity, positive predictive value, and negative predictive value.
Analyses were performed using the commercial statistical
software SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA).
Contingency analysis was by Chi-square test or Fisher’s exact
test. The Mann–Whitney U-test was used to compare nonpara-
metric distribution of the SFC among different groups. All of the
signiﬁcance tests were two-sided, and a p-value of <0.05 was
considered to be statistically signiﬁcant.
3. Results
3.1. Determination of the cutoff value for positivity
To determine the sensitivity and speciﬁcity of the rCFP-10/
ESAT-6 ELISPOT assay in the diagnosis of spinal TB, we comparedthe ELISPOT responses of 30 patients with spinal TB to those from
48 controls (20 non-TB disease patients and 28 healthy controls).
Receiver operating characteristic curve analysis was performed to
determine the optimal cutoff value of the ELISPOT assay, balanced
with the highest possible positive rate for patients with spinal TB
and the lowest positive rate for controls (data not shown). Based on
this concept, the cutoff value for the rCFP-10/ESAT-6 ELISPOT assay
was 15 SFC per 250 000 cells. Therefore, the ELISPOT assay was
scored as positive when the number of SFC in the stimulated wells
minus the number in the negative control wells was 15 or when
there were at least twice as many SFC as in the negative control
well, and scored as negative when the number of SFC in the
stimulated wells minus the number in the negative control wells
was <15.
3.2. Clinical diagnostic value of the rCFP-10/ESAT-6 ELISPOT assay for
spinal TB
Of 91 patients with suspected spinal TB with valid ELISPOT
results, 52 were categorized into the spinal TB group and 39 into
the non-TB disease group. The ELISPOT results and the number of
SFC in the two groups are shown in Figures 1 and 2. The results of
conventional diagnostic tests and ELISPOT assays are shown in
Table 2. We found that 35.7% and 57.5% of spinal TB patients were
positive for AFB staining and cultures for M. tuberculosis,
respectively. Overall, 41 (87.2%) of 47 specimens from these
patients had histopathological features consistent with a diagnosis
of TB infection. Among the 23 patients with culture-conﬁrmed
spinal TB, pulmonary TB involvement was found in two (8.7%). All
of the patients with culture-conﬁrmed spinal TB had positive
ELISPOT results.
Among the spinal TB patients and non-TB disease patients, the
overall sensitivity, speciﬁcity, positive predictive value, and
negative predictive value for spinal TB diagnosis by the PPD skin
Figure 2. Spread of spot-forming cells (SFCs) above the negative control/2.5  105
peripheral blood mononuclear cells (PBMCs) in response to recombinant CFP-10/
ESAT-6 fusion protein in 52 spinal TB patients and 39 non-spinal TB patients. The
bold lines indicate the median values for the respective groups.
Table 2
Comparison of 52 patients with spinal tuberculosis detected by PPD skin tests, antibod
PPD skin testsa Antibo
Pos Neg Total Pos 
ELISPOT-positive 29 14 43 26 
ELISPOT-negative 3 6 9 3 
Total 32 20 52 29 
PPD, puriﬁed protein derivative; ELISPOT, enzyme-linked immunospot assay. Data are 
a ELISPOT vs. PPD skin test (Chi-square test): p = 0.013.
b ELISPOT vs. antibody test (Chi-square test): p = 0.003.
c ELISPOT vs. histopathology detection (Chi-square test): p = 0.688.
Table 3
Factors associated with number of SFC and positive rate of ELISPOT among the 52 pat
ELISPOT assay 
Number of cases SFC U p
Sex
Male 31 38.4  32.4 302.5 0.
Female 21 44.9  39.1 
Age, years
<60 39 43.8  35.0 191.5 0.
60 13 32.7  35.0 
Medical history, months
<6 19 48.2  45.8 306.5 0.
>6 33 36.9  26.9 
BMI, kg/m2
<16 10 19.4  12.5 102.5 0.
17–25 42 46.2  36.8 
>25 0
Coexisting diseases
No 12 33.2  33.4 191.0 0.
Yes 40 43.4  35.6 
Lymphocyte count, cells/mm3
<1000 9 29.7  22.6 156.5 0.
1000 43 43.4  36.9 
Paravertebral abscess
No 23 27.6  19.9 225.5 0.
Yes 29 47.6  35.8 
SFC, spot-forming cells; ELISPOT, enzyme-linked immunospot assay; BMI, body mass i
a Mann–Whitney U-test was used to compare nonparametric distribution of the SFC
b Pearson Chi-square test was used to compare the positive rate of two groups.
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comparison, the sensitivity, speciﬁcity, positive predictive value,
and negative predictive value for spinal TB diagnosis by the
ELISPOT assay were 82.7%, 87.2%, 89.6%, and 79.1%, respectively.
The overall sensitivity of the ELISPOT assay was higher than that of
the PPD skin test and antibody detection test (p < 0.05).
3.3. Clinical characteristics associated with the rCFP-10/ESAT-6
ELISPOT results in spinal TB patients
Table 3 shows the clinical factors associated with the number of
SFC and positive rate of the ELISPOT assay among the 52 patients
with spinal TB. The mean number of SFC in spinal TB cases aged
<60 years was higher than that of the spinal TB cases aged 60
years. The diagnostic sensitivity of the ELISPOT assay in TB cases
aged <60 years was signiﬁcantly higher (89.7%) than that of the TB
cases aged 60 years (61.5%) (p < 0.05). Likewise, the mean
number of SFC in spinal TB patients with mild malnutrition and
normal nutrition (BMI 16–25 kg/m2) was signiﬁcantly higher than
that of spinal TB patients with severe malnutrition (BMI <16 kg/
m2). However, the overall diagnostic sensitivity of the ELISPOT
assay was not signiﬁcantly different (p > 0.05). For these patients,
the mean number of SFC in spinal TB patients with abscesses was
47.6  35.8, in contrast to 27.6  19.9 in spinal TB patients without
abscesses (p < 0.05).y detection, histopathology detection, and ELISPOT
dy detectionb Histopathology detectionc
Neg Total Pos Neg Total
17 43 37 2 39
6 9 4 4 8
23 52 41 6 47
number of subjects.
ients with spinal tuberculosis
ELISPOT assay
a No. of positive (positive rate) Chi-square p b
688 26 (83.9%) 0.075 0.785
17 (80.9%)
190 35 (89.7%) 5.419 0.020
8 (61.5%)
894 15 (78.9%) 0.293 0.588
28 (84.4%)
013 7 (73.9%) 1.394 0.238
36 (85.7%)
287 9 (75.0%) 0.645 0.422
34 (85.0%)
371 7 (77.8%) 0.184 0.688
36 (83.7%)
046 17 (73.9%) 2.221 0.136
26 (89.7%)
ndex. Data are number of subjects.
 (mean  standard deviation).
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surgery
Additional responses were evaluated in a consecutive subset of
15 spinal TB patients at 2 days before and after surgery. Six spinal
TB patients only underwent focal cleaning. The remaining nine
spinal TB patients underwent one-stage anterior debridement and
bone graft plus anterior or posterior instrumentation. The median
rCFP-10/ESAT-6 (43.0  23.6) response was slightly lower after
surgery than before surgery (48.5  29.9), but this failed to reach
statistical signiﬁcance (p > 0.05). There were three spinal TB patients
with an atypical clinical presentation in this study. These patients
presented with a paravertebral giant cold abscess without obvious
bony lesion. The median rCFP-10/ESAT-6 fusion protein response was
noticeably lower after surgery (40, 20, and 77 spots per 250 000
PBMCs) than before surgery (72, 53, and 130 spots per 250 000
PBMCs).
4. Discussion
Despite the availability of an inexpensive and effective therapy,
TB continues to be a major global public health problem. Early
diagnosis plays a vital role in controlling TB. Delayed diagnosis
results in more extensive disease, complications, and increased
mortality.16 Spinal TB usually presents in a slowly indolent manner
with nonspeciﬁc clinical presentations, making the diagnosis a
great challenge for clinicians. A deﬁnite diagnosis of spinal TB
depends on the demonstration of M. tuberculosis by culture from
biopsy specimens. It is reported that PPD positivity is 90% in
immunocompetent patients with skeletal TB, but this test is much
less sensitive in immunosuppressed patients.17 Among the 52
patients with spinal TB in this study, an immunocompromised
condition was found in 10 patients. Only two of these patients had
positive PPD skin test results. This factor might be responsible for
the somewhat disappointing sensitivity of the PPD skin test in our
study. Conventional methods for the diagnosis of spinal TB,
however, are often inefﬁcient. Thus, rapid, sensitive, and speciﬁc
diagnostic tests for spinal TB are required. Previous studies have
shown that, with blood samples, the ELISPOT assay has a high
sensitivity for diagnosing extrapulmonary TB,18,19 including
osteoarticular TB, cutaneous TB, TB lymphadenitis, and TB
pleurisy.7,8,20–22 We therefore conducted an observational study
to assess the diagnostic value of a laboratory-developed rCFP-10/
ESAT-6 ELISPOT assay in spinal TB.
In this study, we used the rCFP-10/ESAT-6 fusion protein as the
stimulating antigen. It is less costly to prepare and detect than
bulk peptides. The advantage of this construction is that the rCFP-
10/ESAT-6 fusion protein has improved molecular ﬂexibility with
decreased interaction between the two component proteins
during protein folding, thus ensuring that the spatial conforma-
tion of the fusion protein is consistent with that of native CFP-10
and ESAT-6.14 The sensitivity of a laboratory-developed rCFP-10/
ESAT-6 ELISPOT assay for patients with active pulmonary TB was
recently reported to be 67.7%.9 In this study, we found that the
sensitivity of the ELISPOT assay for diagnosing spinal TB was
82.7%, which was higher than that of the PPD skin test, AFB smear,
and M. tuberculosis culture from a biopsy sample. The differences
in sensitivity may be due to various degrees of immune response
at different sites of TB.11 A previous study showed that the
ELISPOT assay had a sensitivity of 86.7% and a speciﬁcity of 61.9%
for diagnosing skeletal TB. What’s more, the ELISPOT assay had a
sensitivity of 100% for diagnosing spinal TB.8 The results suggest
that our ELISPOT assay has potential utility in the diagnosis of
spinal TB.
Histopathological ﬁndings, including granulomatous inﬂam-
mation, caseating necrosis, and AFB, usually indicatemycobacterial infection and are helpful in diagnosing TB. In
this study, 47 patients with spinal TB underwent an invasive
procedure to obtain a tissue specimen for the purpose of
diagnosis, and specimens from 41 (87.2%) of these patients
had positive histopathological features. Thirty-seven of 41
patients with positive pathologic ﬁndings had positive ELI-
SPOT assays. Therefore, our ﬁndings suggest that, as a
relatively less invasive tool than tissue biopsy, the ELISPOT
assay would be a useful adjunct to current tests for the
diagnosis of spinal TB.
In this study, we found that age, emaciation, and paravertebral
abscess were associated with the number of SFC or the positive rate
of ELISPOT in spinal TB patients. A previous study showed that
aging is a risk factor for false-negative results.23 In another study
conducted by Liao et al.24 using an ELISPOT assay, increasing age
was associated with false-negative results. In our study, the
diagnostic sensitivity of the ELISPOT assay in TB cases aged <60
years was higher (89.7%) than that in TB cases aged 60 years
(61.5%). Likewise, the low BMI in our study population was
associated with a weak response to rCFP-10/ESAT-6 in the ELISPOT
assay. Severe wasting disease or malnutrition causes unhealthy
emaciation with an extremely low BMI, debilitating the patients
and also suppressing the systemic immune response.25 Hang et al.,
also found emaciation to be a risk factor for false-negative results
in the ELISPOT assay.26 These risk factors might responsible for the
somewhat disappointing sensitivity of our ELISPOT assay. Para-
vertebral abscess was one of the most common clinical symptoms
in spinal TB.27 In this study, there was a trend for the rCFP-10/
ESAT-6 fusion protein response to be greater in spinal TB patients
with abscesses than in spinal TB patients without abscesses. A
potential mechanism could underlie this ﬁnding. Spinal TB with
abscess usually has an insidious onset and slow progression.
Chronic forms of TB have been associated with intermediate to
high antigenic load and a robust host immune response. A previous
study showed that this mechanism in extrapulmonary TB varies
between different sites of disease.28 Thus, the immune response of
spinal TB with abscesses may be more efﬁcient than that of spinal
TB without abscesses at eluting IFN-g-producing T-cells. However,
the overall diagnostic sensitivity of the ELISPOT assay was similar
in the two groups.
Sequential monitoring of ELISPOT responses may also be useful
in monitoring the response to anti-TB chemotherapy.29 The role of
rCFP-10/ESAT-6 ELISPOT in monitoring the efﬁcacy of the surgical
treatment of spinal TB has not been reported. In our study, the
median rCFP-10/ESAT-6 fusion protein responder T cells after
surgery decreased slightly in comparison to that before surgery,
but the difference was not signiﬁcant (p > 0.05). Three spinal TB
patients with an atypical clinical presentation were recruited into
our study. These patients presented with a giant cold abscess
without obvious bony lesion. To our surprise, the response to rCFP-
10/ESAT-6 in these three patients was obviously lower after
surgery than before surgery. The aim of the operation was the
debridement of the cold abscess. Thus, we analyzed the impact that
the surgical treatment might have in reducing the response to the
speciﬁc antigens in these atypical spinal TB patients. However, the
speciﬁc mechanism is unknown. So, further studies are needed to
assess the clinical value of the ELISPOT assay for monitoring the
efﬁcacy of surgical treatment in cases of atypical spinal TB.
Our study had several limitations. First, the drawbacks of the
ELISPOT assay are the relatively high labor intensity in performing
the test and the inability of the test to differentiate between active
and latent TB infection (LTBI). Therefore, a positive ELISPOT assay
result might be due to LTBI or a previous history of TB. The inability
of this test to discriminate active TB from LTBI might limit its
application in the detection of active TB, especially in countries
with a high prevalence of TB, such as China. Second, the
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diagnosis of spinal TB was not evaluated by parallel comparison
with the commercial QuantiFERON-TB Gold In-Tube (QFT-G) and
T-SPOT.TB (Oxford Immunotec). In contrast to the wide use of IFN-
g assays for the diagnosis of M. tuberculosis infection in Europe and
America, the utilization of IFN-g assays in China is scarce because
of the high cost of these kits. We plan to evaluate the performance
of our laboratory-developed rCFP-10/ESAT-6 ELISPOT assay in
spinal TB by parallel comparison with the commercial T-SPOT.TB
assay (Oxford Immunotec). Third, we did not perform a subgroup
analysis in immunocompromised patients with suspected spinal
TB because only limited numbers of immunocompromised
patients were enrolled in this study. Thus, further studies are
needed on the diagnostic performance of our laboratory-developed
ELISPOT assay in immunocompromised patients.
In conclusion, the rCFP-10/ESAT-6 ELISPOT assay appears to be
useful as a complementary method in the diagnosis of spinal TB.
Although the difference in rCFP-10/ESAT-6 fusion protein respond-
er T cells before and after the surgery for spinal TB was not
signiﬁcant, this assay might be useful for monitoring the efﬁcacy of
surgical treatment of atypical spinal TB with giant cold abscess.
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